Pharmaceutical

BioVersys and GSK expand their partnership for TB treatment alpibectir

BioVersys and GSK have announced the expansion of their partnership to expedite the clinical development of alpibectir for tuberculosis (TB).

May 9, 2024 - 00:00
BioVersys and GSK expand their partnership for TB treatment alpibectir
BioVersys and GSK have announced the expansion of their partnership to expedite the clinical development of alpibectir for tuberculosis (TB).
Read the original article

Tags:

Previous Article

How six trends are driving pharmaceutical milling  

Next Article

TerSera’s ZOLADEX LA gains Health Canada approval for breast cancer

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA to start review of subcutaneous Entyvio for Crohn’s disease

FDA to start review of subcutaneous Entyvio for Crohn’s...

Sep 13, 2023

Listen: Racing for gene therapy, a pioneering approval, & startups in the lurch

Listen: Racing for gene therapy, a pioneering approval,...

Aug 17, 2023

Botulinum battle heats up with FDA approving Daxxify for cervical dystonia

Botulinum battle heats up with FDA approving Daxxify fo...

Aug 14, 2023